817 related articles for article (PubMed ID: 33140086)
1. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.
Muecksch F; Wise H; Batchelor B; Squires M; Semple E; Richardson C; McGuire J; Clearly S; Furrie E; Greig N; Hay G; Templeton K; Lorenzi JCC; Hatziioannou T; Jenks S; Bieniasz PD
J Infect Dis; 2021 Feb; 223(3):389-398. PubMed ID: 33140086
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
Rathe JA; Hemann EA; Eggenberger J; Li Z; Knoll ML; Stokes C; Hsiang TY; Netland J; Takehara KK; Pepper M; Gale M
J Infect Dis; 2021 Apr; 223(7):1120-1131. PubMed ID: 33367830
[TBL] [Abstract][Full Text] [Related]
3. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
[TBL] [Abstract][Full Text] [Related]
4. Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2.
Suhandynata RT; Hoffman MA; Huang D; Tran JT; Kelner MJ; Reed SL; McLawhon RW; Voss JE; Nemazee D; Fitzgerald RL
Clin Chem; 2021 Jan; 67(2):404-414. PubMed ID: 33084854
[TBL] [Abstract][Full Text] [Related]
5. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
[TBL] [Abstract][Full Text] [Related]
7. Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19.
Tian L; Elsheikh EB; Patrone PN; Kearsley AJ; Gaigalas AK; Inwood S; Lin-Gibson S; Esposito D; Wang L
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800363
[TBL] [Abstract][Full Text] [Related]
8. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
[TBL] [Abstract][Full Text] [Related]
9. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies.
James J; Rhodes S; Ross CS; Skinner P; Smith SP; Shipley R; Warren CJ; Goharriz H; McElhinney LM; Temperton N; Wright E; Fooks AR; Clark TW; Brookes SM; Brown IH; Banyard AC
Viruses; 2021 Apr; 13(4):. PubMed ID: 33924168
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
[TBL] [Abstract][Full Text] [Related]
12. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.
Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B
Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342
[TBL] [Abstract][Full Text] [Related]
13. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
14. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
[TBL] [Abstract][Full Text] [Related]
15. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
[TBL] [Abstract][Full Text] [Related]
17. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.
von Rhein C; Scholz T; Henss L; Kronstein-Wiedemann R; Schwarz T; Rodionov RN; Corman VM; Tonn T; Schnierle BS
J Virol Methods; 2021 Feb; 288():114031. PubMed ID: 33275926
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J
Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195
[TBL] [Abstract][Full Text] [Related]
19. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
20. A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
Cameron A; Porterfield CA; Byron LD; Wang J; Pearson Z; Bohrhunter JL; Cardillo AB; Ryan-Muntz L; Sorensen RA; Caserta MT; Angeloni S; Hardy DJ; Zand MS; Pecora ND
J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
